Welcome to Markets Desk, here's what's moving the needle right now.
Goldman Sachs is warning investors that the artificial intelligence capital expenditure cycle is getting ahead of itself — and that's a risk, not just a rally. The bank says forecasts of nine hundred twenty billion dollars in AI-related spending by two thousand twenty seven are likely too conservative, meaning the gap between what's being spent and what's being earned is only going to widen. That's a valuation pressure investors can't ignore.
Shifting from tech infrastructure to commodities, the whey protein market is flashing a genuine supply crunch. Nutrition companies are struggling to source high-protein whey as the wellness boom and the GLP-one drug wave drive demand far beyond what the industry was built to handle. Prices are climbing sharply, and that's a margin story for anyone in the consumer health or supplement space.
And on the policy front, a sweeping proposed rewrite of federal grant rules has the scientific community on edge. The Office of Management and Budget, alongside roughly forty agencies including the National Science Foundation and NASA, wants to restructure how federal research dollars flow — a potential shift away from the peer-review independence that has defined American science for decades. The downstream effects on research-driven equities could be significant.
That's the tape. Markets Desk, signing off the floor.
